LAVAL, QC – ProMetic Life Sciences Inc. has released interim results from its open label Phase 2 clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF) demonstrating that PBI-4050 is safe and well tolerated in patients suffering from the condition.
The objective of the study was to provide early evidence of clinical benefits of PBI-4050 treatment whether used alone or in addition to either nintedanib or pirfenidone.
As part of the trial, 40 patients are enrolled in six sites across Canada. At this time, the company is reporting on the first 30 patients that have completed their 12 weeks of treatment.
“We are very pleased with the results to date from this study as they provide us with very important data points relating to efficacy and safety” stated Dr. John Moran, chief medical officer of ProMetic. “(The early evidence) compares favourably to that of the pirfenidone or nintedanib treatment reported in the ASCEND trial and in the two INPULSIS trials, respectively.”
He adds that the further good news is that PBI-4050 is very well tolerated by IPF patients whether used alone or in combination with nintedanib or pirfenidone.